<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02148562</url>
  </required_header>
  <id_info>
    <org_study_id>S56121</org_study_id>
    <secondary_id>12G1714N</secondary_id>
    <nct_id>NCT02148562</nct_id>
  </id_info>
  <brief_title>Assessment of Hepatitis B Virus Intra-host Population and Host-specific Immune Marker Diversity</brief_title>
  <official_title>Assessment of Hepatitis B Virus Intra-host Population and Host-specific Immune Marker Diversity With Next-generation Sequencing: From Chronic Infection to End-stage Liver Disease and Liver Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fund for Scientific Research, Flanders, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this project proposal, the investigators will investigate the genetic alterations of
      Hepatitis B Virus (HBV) strains circulating in Belgian patients who developed end stage liver
      disease. Additionally, the investigators will compare and link these data sets with three
      genetic factors involved in immune system response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project proposes to identify and characterize the genetic alterations associated with
      intra-host evolution of HBV from a chronically infection status to an end-stage liver disease
      status.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>genetic variants of Hepatitis B</measure>
    <time_frame>6 months</time_frame>
    <description>Virus variants will be identified by amino acid or nucleotide variations (insertions or deletions) in different Open Readind Frames (ORFs) of the HBV genome by using next-generation sequencing.
Comparison of virus variants within one patient Comparison of virus variants between patients with end stage liver disease and patients with a chronic Hepatitis B infection.
Determination of the viral load by quantitative Polymerase Chain Reaction (PCR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>genetic variation in host-specific immune markers</measure>
    <time_frame>at day of enrollment</time_frame>
    <description>Amplification of HLA-A, HLA-B, HLA-C class I and HLA class II using PCR methods and next-generation sequencing
Amplification of KIR genes: 2DS1, 2DS2, 2DS3, 2DS4, 2DS5, 3DS1 and 1D, 2DL1 2DL2, 2DL3, 2DL5 and 3DL1 using PCR methods and next-generation sequencing
Amplification of SNPs in TNF alfa, TGF beta1 and IFN-R using PCR methods and next-generation sequencing</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">274</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Hepatitis B, Chronic</condition>
  <condition>End Stage Liver Disease</condition>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>Chronic Hepatitis B</arm_group_label>
    <description>Diagnosis of Hepatitis B related liver disease in a pre-advanced stage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>End stage liver disease</arm_group_label>
    <description>Diagnosis of advanced liver disease related to Hepatitis B</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with liver disease related to Hepatitis B in a pre-advanced (chronic infection)
        and advanced stage (end-stage liver diseases) treated at the Hepatology Department of
        University Hospital of Leuven
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Study group:

          -  Clinical diagnosis of advanced liver disease related to chronic Hepatitis B infection
             (cirrhosis, hepatocellular carcinoma,..)

          -  Availability of serum samples

        Control group:

          -  Clinical diagnosis of liver disease related to chronic Hepatitis B infection in a
             pre-advanced stage

          -  Matched demographic and geographic characteristics to study group

          -  Availability of serum samples

        Exclusion Criteria:

          -  Liver disease caused by other hepato-tropic viruses

          -  Patients with auto-immune diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MahmoudReza Pourkarim, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven campus Gasthuisberg, Herestraat 49. 3000 Leuven, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals Leuven campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <state>Flemish Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2014</study_first_submitted>
  <study_first_submitted_qc>May 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2014</study_first_posted>
  <last_update_submitted>May 22, 2014</last_update_submitted>
  <last_update_submitted_qc>May 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>MahmoudReza Pourkarim</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

